Medigen Vaccine Biologics (ROCO:6547) Total Stockholders Equity : NT$3,859.1 Mil (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Medigen Vaccine Biologics Total Stockholders Equity?

Medigen Vaccine Biologics's Total Stockholders Equity for the quarter that ended in Sep. 2024 was NT$3,859.1 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Medigen Vaccine Biologics's Book Value per Share for the quarter that ended in Sep. 2024 was NT$11.74. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Medigen Vaccine Biologics's Debt-to-Equity for the quarter that ended in Sep. 2024 was 0.08.

Medigen Vaccine Biologics Total Stockholders Equity Historical Data

The historical data trend for Medigen Vaccine Biologics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Vaccine Biologics Total Stockholders Equity Chart

Medigen Vaccine Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

1,366.78

3,141.41

4,676.06

5,029.01

3,846.58

Medigen Vaccine Biologics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Stockholders Equity	Get a 7-Day Free Trial															4,414.44	3,846.58	3,774.80	3,845.96	3,859.11

Medigen Vaccine Biologics (ROCO:6547) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Medigen Vaccine Biologics's Book Value per Share for the quarter that ended in Sep. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3859.105	-	0)	/	328.704
	=	11.74

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Medigen Vaccine Biologics's Debt-to-Equity for the quarter that ended in Sep. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(34.586	+	256.988)	/	3859.105
	=	0.08

Medigen Vaccine Biologics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Medigen Vaccine Biologics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigen Vaccine Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Vaccine Biologics Corp (ROCO:6547) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 16, Neihu Road, Lane 120, Floor 7, Section 1, Neihu District, Taipei, TWN, 11493

Website

https://www.medigenvac.com

Medigen Vaccine Biologics Corp is a biopharmaceutical company focusing on developing and producing vaccines and biologics. It is engaged in developing IP-protected cell-culture technologies for vaccine manufacturing. The company develops vaccines and affordable biosimilars to prevent regional infectious diseases. The group generates revenue from manufacturing and selling a range of Covid-19 vaccines and Covid-19 test kits and provides technical services on cellular therapy product quality and cell culture tests.

Medigen Vaccine Biologics Headlines

No Headlines